Table 6 Overview of clinical studies using oral etoposide in advanced ovarian cancer regarding effective median dose intensity of oral etoposide and response rate
Schedule of etoposide | Dose escalation of oral etoposide planned | Effective median dose intensity (mg m−2 week−1) | Response rate (%) | Line of therapy | |
|---|---|---|---|---|---|
Garrow et al (1992) | 50 mg m−2 day−1 × 21 days q 4 weeks | 175 | 20 | Third | |
De Wit et al (1994) | 50 mg m−2 day−1 × 21 days q 4 weeks | 218 | 16 | Second, third | |
Kavanagh et al (1995) | 50 mg m−2 day−1 × 21 days q 4 weeks | Yes | 247 | 0 | Fifth |
Rose et al (1998) | 50 mg m−2 day−1 × 21 days q 4 weeks | Yes | 263 | 31 | Second |
Seymour et al (1994) | 100 mg day−1 × 7 days q 3 weeks | Yes | 267 | 24 | Second, third |
Tuxen et al (1997) | 170 mg m−2 day−1 × 5 days q 3 weeks | Yes | >283 | 48 | First |
Baur et al | 75 mg m−2 day−1 × 10 days q 3 weeks | Yes+use of GM-CSF | 292 | 44 | Second |
